Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1948 1
1949 2
1950 2
1952 2
1953 3
1954 1
1956 1
1958 3
1959 1
1960 2
1961 2
1962 3
1964 2
1965 3
1966 2
1967 3
1968 5
1969 7
1970 6
1971 7
1972 9
1973 8
1974 4
1975 7
1976 5
1977 8
1978 7
1979 2
1980 9
1981 5
1982 4
1983 4
1984 5
1985 4
1986 5
1987 5
1988 9
1989 8
1990 18
1991 27
1992 22
1993 33
1994 22
1995 28
1996 38
1997 41
1998 35
1999 38
2000 46
2001 50
2002 68
2003 63
2004 70
2005 79
2006 95
2007 99
2008 101
2009 130
2010 166
2011 180
2012 147
2013 147
2014 124
2015 125
2016 100
2017 87
2018 95
2019 106
2020 144
2021 118
2022 111
2023 126
2024 120
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,822 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: schreiber s. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
The Rise of Molecular Glues.
Schreiber SL. Schreiber SL. Cell. 2021 Jan 7;184(1):3-9. doi: 10.1016/j.cell.2020.12.020. Cell. 2021. PMID: 33417864 Free article.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. Among authors: schreiber s. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.
Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC; International Inflammatory Bowel Disease Genetics Consortium; Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW. Cleynen I, et al. Among authors: schreiber s. Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18. Lancet. 2016. PMID: 26490195 Free PMC article.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. Among authors: schreiber s. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Sandborn WJ, et al. Among authors: schreiber s. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. N Engl J Med. 2012. PMID: 23075178 Free article. Clinical Trial.
1980s Camelot.
Schreiber SL. Schreiber SL. J Antibiot (Tokyo). 2019 Jun;72(6):323. doi: 10.1038/s41429-019-0174-z. Epub 2019 May 27. J Antibiot (Tokyo). 2019. PMID: 31130725 No abstract available.
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL. Zou Y, et al. Among authors: schreiber sl. Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9. Nat Commun. 2019. PMID: 30962421 Free PMC article.
Reply.
Aden K, Schreiber S, Rosenstiel P. Aden K, et al. Among authors: schreiber s. Gastroenterology. 2020 Apr;158(5):1512-1513. doi: 10.1053/j.gastro.2020.02.021. Epub 2020 Feb 15. Gastroenterology. 2020. PMID: 32068024 No abstract available.
2,822 results